Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furmonertinib in Advanced NSCLC With Brain Metastases
NCT05465343Phase 2Completed
- Sponsor
- Peking Union Medical College
- Start
- Jul 2022
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of furmonertinib in non-small cell lung cancer (NSCLC), sponsored by Peking Union Medical College. Started Jul 2022; status: completed.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05465343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05465343.